This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator.
Specific Aims : The primary objective is to examine whether IGIV-C, the investigational biologic, 10%, given at three levels, 0.5, 1, or 2 gm/kg is safe and effective in the inhibition of donor specific +CMX pretransplant and wheter this treatment will allow for successful kidney transplantation.
Showing the most recent 10 out of 515 publications